Background: Constipation is an important issue for patients receiving palliative care within specialist palliative care settings. Questions and ambiguity, however, persist about international best practice and management. Aim: To synthesise the current evidence base on the assessment and management of constipation for palliative care patients within a specialist palliative care setting. Design: This is a systematic review. Data sources: MEDLINE, Embase, CINAHL, Scopus and Cochrane databases were systematically searched in April 2017 for empirical studies, written in English, on the assessment and management of constipation in specialist palliative care settings, published between 2007 and 2017. Two researchers independently reviewed and critically appraised all studies, conducted data extraction, and undertook a thematic analysis. Results: In total, 13 studies were included in the review comprising randomised trials (n = 3), observational (n = 4) and descriptive studies (n = 6). Most research was conducted in specialist palliative care units, targeting either healthcare professionals or patients. The analysis highlighted a lack of standard definition of constipation, raising questions on the existence and comparability of baseline prevalence figures, the physical and psychological impact on patients, resource impact on staff and service, the subjective and objective methods of assessing constipation, and key aspects of constipation management, including a lack of focus on non-pharmacological management in this setting.
• • Constipation causes considerable suffering, either as a direct result of physical symptoms or due to related social and psychological problems such as embarrassment. Despite this, constipation remains poorly recognised and inadequately treated by healthcare providers. • • Uncertainty persists about the 'best' management of constipation for palliative care patients.
What this paper adds?
• • The review demonstrates the lack of standard assessment of constipation for patients in specialist palliative care (SPC) settings at the end of life. • • Clinicians experience challenges in the assessment of constipation and the need to combine patient assessment alongside physical examination and, potentially, the use of radiology. • • Clinician response results in an emphasis on pharmacological management; however, consideration around non-pharmacological aspects and impact of dietary and lifestyle factors is also relevant for the management of constipation in this population.
Introduction
Palliative care seeks to improve the quality of life and well-being of adults and children with a life-limiting or terminal illness, helping them live as fully as they can for the time they have left. 1 A central part of this care includes the management of pain and symptoms, 2 seeking to prevent and relieve suffering by early identification and effective assessment and treatment of pain and other problems, physical, psychosocial and spiritual. 3 Constipation is a frequent problem experienced by people with palliative care needs, with overall prevalence rates ranging from 32% to 87% in palliative patients. 4 This variation may be attributable to the variation in the patient population assessed and the lack of standardised definition of constipation across studies. 4 A significant number of people will experience constipation during their palliative care disease trajectory, although it is noted to be more problematic in advanced disease. 5, 6 Constipation causes considerable suffering, either as a direct result of physical symptoms or due to related social and psychological problems such as embarrassment. 7 Despite this, constipation remains poorly recognised and inadequately treated by healthcare providers. Barriers include lack of understanding, embarrassment, the subjective report from the patient, the lack of an agreed-upon definition, a range of assessment tools within clinical practice and limited use of shared diagnostic criteria (such as the Rome III criteria) between healthcare professionals. 8 Within the palliative care population, there are multiple factors commonly associated with increased risk of constipation including physical illness, hospitalisation, reduced fluid intake and the use of opioids. 4 Internationally, uncertainty persists about the 'best' management of constipation for palliative care patients. Some guidelines do exist globally and at national and regional levels, but the recommendations are varied, both in content and in level of detail. For example, while there are European clinical practice recommendations for the management of constipation in palliative care, 4 a European Report in Constipation 9 found that, across Europe, fragmented approaches to constipation management existed. France offers clear guidelines for constipation in older adults but not palliative care specific; the Netherlands have guidelines for general practitioners but without a focus on older adults; and the Czech Republic, Italy, and Germany have no standards or guidelines for constipation. This raises the issue with the various guidelines of the lack of specific information for palliative care patients, therefore the lack of transferability to palliative settings. Other examples include the Australian guidelines for constipation in children, 10 Australian guidelines for antenatal constipation, 11 and global guidelines for all adult patients. 12 Cultural differences also need to be considered in relation to the guidelines. For example, researchers in Asia 13 reported constipation to differ between Asia and Western countries due to differences in patient perception and self-management, dietary practices, intestinal physiology, and healthcare infrastructure.
While constipation is an important issue for palliative care patients and prevalence is variable, uncertainty still persists in clinical practice regarding the assessment and management of constipation in SPC settings.
Aim
To synthesise the current evidence base on the assessment and management of constipation for palliative care patients in an SPC setting.
Methods
A systematic review was undertaken utilising Aveyard's 14 guide to undertaking a literature review in health and social care and the PRISMA checklist. 15 This approach was chosen to address a defined research aim using empirical evidence within a pre-specified set of eligibility criteria. A range of search techniques were used including electronic database searching, reference list checking, contacting experts, and citation searching. 16 
Search strategy
Studies were identified in April 2017 by systematic database searches in conjunction with a subject librarian, scanning reference lists of included articles, and consultation with the project's steering group (clinical and academic experts in constipation and hospice care 4 
Search outcome
The initial search retrieved 135 articles across all databases, with 103 articles remaining following the removal of duplicates. Title and abstract screening against the inclusion criteria was completed independently by two reviewers (D.P. and F.H.), and following the removal of irrelevant articles, 15 articles remained. The full texts of these articles were retrieved and independently assessed for relevance. Four articles were excluded for the following reasons: not empirical, 1 and the research was conducted outside a hospice setting. 3 Two additional articles were identified through reference list screening. In total, 13 articles were included in the final review (Appendix 2).
Quality appraisal was undertaken using the Joanna Briggs Institute (JBI) levels of evidence (the Joanna Briggs Institute, 2014). These include five levels of evidence: experimental, quasi-experimental, observational analytic, observational descriptive and expert opinion/bench research. At all stages of the process, the articles were individually assessed, reviewed and appraised by two members of the research team (D.M. and F.H.), and any disagreements were mediated by a third reviewer (S.M.).
Data extraction and synthesis
Data were extracted using an adapted data extraction form based on the work of Taylor et al. 17 This was piloted and refined as required. Data extraction detailed: study details; location; aims and objectives; sample, methods, data analysis, the aspect of constipation assessment, management, or treatment discussed; and main findings (see Supplementary File). Two authors independently reviewed the included articles to thematically synthesise the key aspects of constipation assessment and management. Thematic synthesis included line-by-line coding of the findings of the primary studies, the categorisation of codes into the descriptive themes of assessment and management, and the development of analytical themes within the descriptive categories (Table 2) . 18 
Results

Characteristics of included articles
The designs of the included studies were three randomised trials, 25, 28, 31 four observational designs, 20, 21, 26, 27 and six descriptive designs. 19, [22] [23] [24] 29, 30 Drawing on the JBI's levels of evidence for effectiveness, two articles were ranked at Of the studies, four were conducted in Canada; 21, 22, 24, 28 four in the United States; 25, 26, 29, 31 and one study was conducted in each of Australia, 20 China, 19 Norway, 23 Taiwan, 27 and the United Kingdom. 30 Specialist palliative care (SPC) units within medical centres, 19 hospitals, 21, 22, 24 and teaching hospitals 20, 27 were the most common locations of research. An SPC unit was referred to in three studies, 22, 25, 30 and a mixture of various hospice care settings were referred to in three further studies. 23, 26, 29 The focus of the studies ranged vastly across studies. The history of constipation and its links to clinical and demographic characteristics was examined by Strassels et al. 26 Bowel habits and their associated factors were also considered by Cheng et al. 19 Four studies focused on constipation treatments including docusate, 28 methylnaltrexone, 25, 31 and oral preparation of petroleum jelly (OPJ). 29 Another study examined the relationship between laxatives and bowel movement frequency. 20 Bowel assessment scales including the Victoria Bowel Performance Scale (BPS) 21, 22 and the Constipation Assessment Scale 24 were analysed in three studies. Palliative care outcomes including symptom prevalence or severity 23, 27 were the focus of two studies, both of which identified constipation as a key symptom or outcome within the abstract. Finally, one study considered the financial cost of managing constipation in patients taking opioids. 30 Three studies recruited patient with advanced cancer, 19, 24, 27 one of which specified they must also be on medication for bowel movement. 19 Five further studies included inpatients who were prescribed laxatives, 20 had constipation scores recorded, 26 or were on opioids. 25, 30, 31 Three studies included all inpatients, 28 or inpatients and outpatients, 22, 23 irrespective of diagnosis or report of constipation. Three studies included healthcare providers including staff nurses 21 and a mixture of nursing, medical, and pharmacy staff. 22, 29 Synthesised thematic findings Constipation assessment. Constipation was identified as one of the most common symptoms, particularly in the case of patients with gastrointestinal (GI) tract cancers, through the assessment of symptom severity in Tai et al.'s study. 27 The frequency of constipation was supported by a retrospective cohort study across the United States which found constipation was assessed an average of four times per person admitted to hospice care. 26 Methods of assessment of constipation varied considerably for those studies whose primary goal focused on assessment. Two studies used a variety of constipation-specific tools and criteria which are well known, such as the Bristol Stool Chart, Constipation Visual Analogue Scale (CVAS), and Rome II diagnostic criteria. 19, 28 Two studies used accepted cut-off points for diagnosing constipation without referencing the specific criteria, for example, number of bowel movements and bowel function. 20, 25 The importance of including the patient's subjective experience of constipation alongside other objective measures was identified in one study as an important element of assessment. 19 Only one study reported the use of rectal examinations, which were done in 24 of 70 admissions over a 6-month period in an SPC unit. 30 Non-standardised tools including a constipation intensity numeric rating scale 26 were also identified as a key component of constipation assessment. Others tools were used which assessed a broader concept but which identified constipation as one of the components, for example, the Palliative Performance Scale (PPS) and a symptom severity reporting form. 27, 28 Three studies had a primary focus on constipation assessment tools including the Victoria BPS 21, 22 and the Constipation Assessment Scale. 24 The Victoria BPS is a bipolar, 9-point, ordinal scale which ranges from +4 (diarrhoea) to −4 (constipation) and considers stool frequency, consistency, and patient ability to control evacuation. In total, 18 test cases were developed by Downing et al., 21 which showed good inter-and intra-rater reliability. The small number of confounding test cases illustrated the need to understand the instructions for the BPS, but overall, it was found to be quick, easy and reliable. Hawley et al. 22 supported these findings, reporting the tool as an acceptable and useful bowel function assessment tool. Interestingly, the tool was modified to remove the reference to the 3-day interval between bowel movements, swapping it for the patient's desired goal for how often they want to have a bowel movement. Nagaviroj et al. 24 compared the patients' scores on the Constipation Assessment Scale with the physicians' interpretations of a plain abdominal radiograph. The findings suggested no correlation between the two different instruments, concluding that objective and subjective assessments could not be considered gold standard when used alone, but rather should be used in conjunction with one another.
Constipation management. Three studies focused on specific medication including docusate, 28 methylnaltrexone for opioid-induced constipation (OIC), 25 and OPJ. 29 A further study examined the relationship between laxatives and bowel movement frequency, 20 and Cheng et al. 19 aimed to evaluate laxative use in advanced cancer patients within an SPC unit. In Cheng et al.'s 19 study, 92% of 225 SPC unit patients were on at least one of the following interventions: laxatives, suppositories, enemas, digital evacuation, 'over-thecounter' medications, Chinese herbal medicine (CHM) or health supplements. It was found that 147 (65.3%) of the patients were on laxatives prescribed by SPC unit doctors. The use of laxatives, enemas, suppositories, digital evacuation, and 'over-the-counter' medications did not significantly differ; however, the proportion of patients receiving CHM or health supplements for constipation was significantly higher in the no constipation group than the constipation and severe constipation group. Laugsand et al. 23 found senna to be the most commonly prescribed laxative in Switzerland (54%), but lactulose was used by 52% in Sweden, 51% in Portugal, 56% in Denmark, 60% in the Netherlands, and 100% in Luxemburg. However, despite 18% of SPC unit patients reporting moderate or severe constipation, approximately a third were not given any drugs for symptom management. In a study of 211 admissions to an SPC unit in Australia, 20 docusate with senna was the most commonly prescribed combination of laxatives (n = 119), followed by docusate with senna and macrogol (n = 86). However, this study found no relationship between the prescription of laxatives and the frequency of documented bowel movements. The authors suggest that this may be caused by a limited number of attempts within palliative care to objectively explore the functional problems of the colon and pelvis which may contribute to constipation. Alternatively, they reported that laxatives were prescribed based on subjective patients' reports.
To assess the efficacy of docusate, Tarumi et al. 28 conducted a randomised, double-blind, placebo-controlled trial of oral docusate in 74 adult hospice patients (75% completed the study). There were no significant differences between the treatment groups in stool frequency, volume, consistency, difficulty or completeness of evacuation, or on the Edmonton Symptom Assessment Scale scores between the groups. Rescue laxatives were needed for many participants, with interventions including bisacodyl suppository, sodium phosphate enema, and lactulose. It was concluded that there was no significant benefit of adding docusate to sennoside, but this may have been attributable to the use of co-interventions including additional laxatives and bowel interventions as required. In addition, the patients were terminally ill with various superimposed conditions which may have resulted in different responses or not responding to docusate treatment.
As a third-line therapy after oral laxatives and suppositories, Tavares et al. 29 found that OPJ produced a bowel movement within 24 h in 88% (n = 117) of cases, with low adverse effects reported. In this study, 67% (n = 237) of healthcare practitioners were familiar with the use of OPJ; however, there was a lack of consistency in the amount of OPJ recommended, from one to four balls per dose at varying intervals. In this study, 72% (n = 106) of surveyed healthcare professionals who currently recommend OPJ would recommend their use in cases of high impaction. While high impaction and hard stools in the rectum were the most likely situations in which OPJ was used, it was not limited to this scenario.
When considering pharmacological management, the role of opioids as a cause of constipation has been identified across multiple studies. Cheng et al. 19 found 60.9% (n = 137) patients were prescribed opioids, and prophylactic prescriptions of laxatives were recommended. Patients not on opioids as compared to patients on strong opioids had similar CVAS scores and description of constipation but had the least laxatives prescribed. The proportion of patients on strong opioids was significantly higher in the severe constipation group (34.3%) than the no constipation group (13.6%) and constipation group (24.6%; p = 0.048). Patients on strong opioids, as compared to weak and no opioids, were significantly younger, had more laxatives prescribed (p < 0.001), and had less prevalence of hard stools. There were no differences in mean CVAS score and their description of constipation symptoms. Patients not on opioids were prescribed with least laxatives, and a higher proportion of them were on 'over-the-counter' medications (28.4%) as compared with patients on weak and strong opioids (6.3% and 8.8%, respectively, p < 0.001). 19 Thomas et al. 31 used a double-blind, randomised, placebo-controlled trial to assess the efficacy of methylnaltrexone in treating OIC. Out of 133 patients enrolled in the trial, 48% of the methylnaltrexone group (receiving 0.15 mg/kg body weight) had laxation within 4 h, compared to 15% of the placebo group (p < 0.001). The median time to laxation was significantly shorter in the methylnaltrexone group, but abdominal pain and flatulence were reported as adverse events. These findings were further supported by Slatkin et al. 25 who explored the efficacy of methylnaltrexone in the treatment of OIC in 154 patients (80% with a cancer diagnosis). In this multicentre, singledose, double-blind, randomised, placebo-controlled trial, three treatment groups were created at a 1:1:1 ratio. One group received 0.15 mg/kg of methylnaltrexone, a second group received 0.3 mg/kg of methylnaltrexone, and the third group received a placebo. The proportion of people who defaecated within 4 h of receiving 0.15 mg/kg, 0.3 mg/kg, and placebo was 67% (95% confidence interval (CI): 47.8%-75.6%), 58.2% (45.1%-71.2%), and 13.5% (4.2%-22.7%); (p < 0.0001 for each methylnaltrexone dose vs placebo), respectively. During the double-blind phase, approximately half of the patients who defaecated reported improvement in stool consistency irrespective of treatment. Administration of methylnaltrexone did not impact on baseline pain, and use of methylnaltrexone did not result in opioid withdrawal. The proportion of patients who reported any improvement in constipation distress at the 4-h assessment was 64.4%, 63.5%, and 34% for 0.15 mg/kg, 0.3 mg/kg, and placebo groups, respectively. Common adverse events included mild-moderate pain, flatulence, nausea, and dizziness, and were directly linked to methylnaltrexone.
The financial cost of constipation management was addressed in one study. 30 This study found the most timeconsuming activity was staff discussion about bowel management, which occurred at least once daily for doctors and twice daily for nurses, and involved up to eight members of staff per discussion. In 50 of 70 admissions in the study, the estimated direct costs relating to the management of constipation was £30 or less, whereas in four admissions, the cost incurred exceeded £100 each. The direct cost of managing constipation was estimated at a mean cost per admission of £29.81 (95% CI: £21.36-£38.26). By contrast, the mean cost of opioid medications per admission was £43.21 (95% CI: £21.81-£64.60).
Discussion
The purpose of this review was to synthesise the current evidence base on the assessment and management of constipation for palliative care patients within SPC settings. Using a systematic approach, 13 international studies were identified which focused on constipation within the SPC setting from the last decade of research. The synthesis of studies demonstrated a lack of standardised assessment which combined the patient's subjective assessment with an objective physical examination. There was a lack of focus on non-pharmacological management, such as considering dietary and lifestyle factors for this population. Additionally, there was a lack of guidance and consideration of constipation management for the dying patient.
Main findings
In terms of assessment and diagnosing constipation, Clark et al. 20 found little relationship between laxative prescribing patterns and frequency of bowel movements, attributable to the limited attempts in palliative care to objectively explore functional problems of the colon. This is supported by the findings of Nagaviroj et al. 24 who found no correlation between the subjective and objective measures of constipation. The limited predictive value of subjective scales for constipation including verbal numerical scales has also been found in other palliative settings, for example, in the hospital and in community settings. 32 While it is important to document a detailed and accurate patient history, and receive subjective perceptions of bowel function, the literature suggests that this must be balanced with objective measurement. This supports the revision to the BPS 22 which changed one of the criteria from 3 days to the patient's goal for bowel movement frequency. These studies paint a picture of the need for subjective assessment of constipation and the importance of taking a detailed history. While the patient's assessment is essential, this should be combined with a physical examination from a qualified healthcare professional, the use of a digital rectal examination where necessary, and potentially the use of radiology to rule out malignant intestinal obstruction. [33] [34] [35] Additionally, the wide variety of tools identified through the findings on assessment draws attention to the need to develop shared tools between healthcare professionals to improve consistency of diagnosis.
The primary focus of constipation management across the studies was pharmacological approaches, including docusate, methylnaltrexone and OPJ. 25, 28, 29, 31 Given the high prevalence of pain and, therefore, opioid use, in this population, it is not surprising that OIC is common. Methylnaltrexone was found to be effective within the hospice setting in treating OIC, further supported by the national guidelines on constipation. 34 However, the findings of this review are inconclusive regarding the most effective pharmacological treatment of constipation. This is supported by the systematic review by Candy et al. 36 on the effectiveness of laxatives, which found limited evidence to support the use of one laxative over another. Instead, it was suggested that the choice be made based on patient preference and circumstance, followed by costeffectiveness when no clear patient preference was evident. 34 A key finding of Laugsand et al. 23 was that a third of patients with moderate to severe constipation were not offered any drug treatment, highlighting the need to ensure all symptoms are addressed without focusing on one prominent symptom.
When considering the relationship between frequency of bowel movements and laxatives, it was noteworthy that there was no discussion focusing on the impact of nonpharmacological measures. 20 This was a similar trend across all studies, none of which raised any methods of non-pharmacological management for constipation despite a recommendation within recent clinical guidelines that this aspect should be considered equally important to pharmacological management. 34 Furthermore, aroma massage has been used in advanced cancer patients in Chinese oncology wards to improve bowel movements and quality of life. 37 This highlights the need for future research to include assessment and implementation of non-pharmacological alongside a pharmacological approach to constipation and to explore the impact of dietary and lifestyle factors in constipation management.
The National Clinical Effectiveness Committee guidelines 34 suggested that rectal intervention is rarely used in the last stage of illness. Constipation management becomes a lower priority and, as consciousness levels deteriorate, oral laxatives should be discontinued. However, the correct timing for the cessation of laxatives in the approach to death remains unclear. 38 The reduced priority of constipation in the dying patient is evident in the literature, with no studies reporting any form of constipation assessment, management or intervention during the last days of life. However, this gap in the literature could be addressed in future research by assessing and addressing what happens in current practice, given the changing priorities in the management of patient care in their last days of life and how this should be approached by healthcare providers.
Strengths and limitations
This review has taken an important area of symptom management in palliative care and focused specifically on the SPC setting, making the findings directly relevant to this clinical area. While all attempts were made to be inclusive of all SPC units within medical centres, palliative care centres and hospice buildings, this cannot be verified based on the available evidence. Similarly, with the many definitions of constipation, and the potential range of phrases such as 'bowel movements', only those articles with constipation in the title, abstract or key words were included in the review. This is acknowledged as a limitation. In addition, the aims of the review had to be kept broad to ensure nothing was missed which may capture an aspect of constipation assessment or management; however, this made it impossible to undertake additional analysis beyond a thematic synthesis. The authors further acknowledge limitations when considering palliative care patients recognising that they comprise a heterogeneous group in terms of diagnosis and function.
What this study adds
A synthesis of the key developments surrounding constipation assessment and management in SPC settings over the last decade has been presented in this review. Key areas, which have been addressed, include the variety of methods to assess constipation and the methods of pharmacological management for constipation. Gaps for future research including the need for a clearer definition of constipation, constipation prevention, non-pharmacological management, and management of constipation for the dying patient have been identified. The results of this review are being used to inform the development of an educational intervention targeting healthcare professionals. The intervention aims to bring together healthcare professionals, to not only provide educational content on the assessment and management of constipation and key challenges, but also assist them in engaging in real-work interaction patient care learning. It is anticipated that such an approach will improve the future assessment and management of this difficult symptom for palliative care patients.
